scholarly journals Longitudinal survival trends of patients with cancer with surgically managed appendicular metastatic bone disease: systematic review

2021 ◽  
Vol 64 (6) ◽  
pp. E550-E560
Author(s):  
Annalise Abbott ◽  
Joseph K. Kendal ◽  
Christopher Hewison ◽  
Shannon Puloski ◽  
Michael Monument
Keyword(s):  
Systematic Review ◽  
Bone Disease ◽  
Metastatic Bone Disease ◽  
Patients With Cancer

Thermal ablation to relieve pain from metastatic bone disease: a systematic review

2019 ◽  
Vol 48 (8) ◽  
pp. 1161-1169 ◽  
Author(s):  
Nicolò Gennaro ◽  
Luca Maria Sconfienza ◽  
Federico Ambrogi ◽  
Sara Boveri ◽  
Ezio Lanza
Keyword(s):  
Systematic Review ◽  
Bone Disease ◽  
Thermal Ablation ◽  
Metastatic Bone Disease ◽  
Relieve Pain

scholarly journals Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis

2012 ◽  
Vol 20 (11) ◽  
pp. 2985-2998 ◽  
Author(s):  
Maria A. Lopez-Olivo ◽  
Nimit A. Shah ◽  
Greg Pratt ◽  
Jan M. Risser ◽  
Elaine Symanski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Bone Disease ◽  
Meta Analysis ◽  
Metastatic Bone Disease

Hypocalcemia associated with metastatic bone disease. A retrospective study

1973 ◽  
Vol 132 (4) ◽  
pp. 539-543 ◽  
Author(s):  
P. Raskin
Keyword(s):  
Retrospective Study ◽  
Bone Disease ◽  
Metastatic Bone Disease

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Should bisphosphonates be the treatment of choice for metastatic bone disease?

2001 ◽  
Vol 28 (4I) ◽  
pp. 35-41 ◽  
Author(s):  
Robert E. Coleman
Keyword(s):  
Bone Disease ◽  
Metastatic Bone Disease

Metastatic bone disease in patients with neuroendocrine tumors

2014 ◽  
Author(s):  
Krystallenia Alexandraki ◽  
Maria Chrysochoou ◽  
Maria Kaltsatou ◽  
Eleftherios Chatzellis ◽  
Marina Tsoli ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Bone Disease ◽  
Metastatic Bone Disease
Sign in / Sign up

Export Citation Format

Share Document